All In Biotech

Drug Trial Radar · NCT05882058

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

DAREON™-5: An Open-label, Multi-center Phase II Dose Selection Trial of Intravenous BI 764532, a DLL3-targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-stage Small Cell Lung Cancer and in Patients With Other Relapsed/Refractory Neuroendocrine Carcinomas

Last checked: Nov 19, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 204 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

204

Planned (sponsor's estimate)

Start

Oct 13, 2023

Primary completion

Dec 17, 2027

Study completion Jun 8, 2028

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
May 31, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults with small cell lung cancer and other neuroendocrine tumours. The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists. The purpose of this study is to find a suitable dose of BI 764532 (also called obrixtamig) that people with advanced cancer can tolerate. 2 different doses of BI 764532 are tested in this study. Another purpose is to check whether BI 764532 can make tumours shrink. BI 764532 is an antibody-like molecule (DLL3/CD3 bispecific) that may help the immune system fight cancer. The study has 3 parts. In Part 1, participants are put into 2 groups randomly, which means by chance. Participants have an equal chance of being in either group. One group gets dose 1 of BI 764532 and the other group gets dose 2 of BI 764532. In Part 2 and Part 3, all participants receive the same dose of BI 764532. Part 2 and Part 3 are open to people with a certain kind of tumour called extrapulmonary neuroendocrine carcinoma. All participants receive BI 764532 as an infusion into a vein when starting treatment. If there is benefit for the participants and if they can tolerate it, the treatment is given up to the maximum duration of the study. During this time, participants visit the study site regularly. The total number of visits depends on how they respond to and tolerate the treatment. The first study visits include an overnight stay to monitor participants´ safety. Doctors record any unwanted effects and regularly check the general health of the participants.

Conditions

  • Small Cell Lung Carcinoma
  • Neuroendocrine Neoplasms
  • Extra-pulmonary Neuroendocrine Carcinoma

Interventions

  • BI 764532, dose 1Drug

    BI 764532, dose 1

  • BI 764532, dose 2Drug

    BI 764532, dose 2

  • Ventana DLL3 RxDx assayDevice

    Ventana DLL3 RxDx assay

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Objective response (OR), defined as a best overall response of confirmed complete response (CR) or confirmed partial response (PR)Time frame: up to 26 months
  2. Part 1: Occurrence of treatment-emergent adverse events (TEAEs) during the on-treatment periodTime frame: up to 26 months
  3. Part 2: Objective response (OR)Time frame: up to 27 months
  4. Part 3: Occurrence of treatment-emergent adverse events (TEAEs) during the on-treatment periodTime frame: up to 23 months
  5. Part 3: Objective response (OR) by blinded independent central reviewTime frame: up to 23 months

Locations

59 sites in 12 countries. Site status is shown where the registry gives one.

  • Infirmary Cancer Care

    Mobile, Alabama · Recruiting

  • Mayo Clinic-Arizona

    Phoenix, Arizona · Recruiting

  • Valkyrie Clinical Trials

    Los Angeles, California · Recruiting

  • University of California San Francisco

    San Francisco, California · Recruiting

  • Mayo Clinic Cancer Center

    Jacksonville, Florida · Recruiting

  • University of Miami

    Miami, Florida · Recruiting

  • H. Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida · Recruiting

  • Indiana University

    Indianapolis, Indiana · Completed

  • University of Kansas Cancer Center

    Westwood, Kansas · Completed

  • University of Kentucky Medical Center

    Lexington, Kentucky · Recruiting

  • University of Maryland School of Medicine

    Baltimore, Maryland · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Completed

  • Mayo Clinic, Rochester

    Rochester, Minnesota · Recruiting

  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health

    New York, New York · Completed

  • Montefiore Medical Center

    The Bronx, New York · Recruiting

  • Virginia Commonwealth University Health- Adult Outpatient Pavilion

    Richmond, Virginia · Recruiting

  • Universitair Ziekenhuis Gent

    Ghent, Belgium · Recruiting

  • UZ Leuven

    Leuven, Belgium · Recruiting

  • Multiprofile Hospital For Active Treatment-Uni Hospital Ltd.

    Panagyurishte, Bulgaria · Completed

  • MHAT Heart and brain

    Pleven, Bulgaria · Completed

  • West China Hospital, Sichuan University

    Chengdu, China · Recruiting

  • Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine

    Hangzhou, China · Recruiting

  • Qilu Hospital, Shangdong University

    Jinan, China · Recruiting

  • 960 Hospital of the Chinese People's Liberation Army

    Jinan, China · Recruiting

  • The Second Affiliated Hospital to Nanchang University

    Nanchang, China · Recruiting

  • Shanghai Chest Hospital

    Shanghai, China · Recruiting

  • HOP Intercommunal

    Créteil, France · Completed

  • Hôpital Cochin

    Paris, France · Completed

  • HOP Civil

    Strasbourg, France · Completed

  • Evangelische Lungenklinik Berlin

    Berlin, Germany · Completed

  • Universitätsklinikum Carl Gustav Carus Dresden

    Dresden, Germany · Recruiting

  • Universitätsklinikum Erlangen

    Erlangen, Germany · Recruiting

  • Asklepios Fachkliniken München-Gauting

    Gauting, Germany · Completed

  • LungenClinic Grosshansdorf GmbH

    Großhansdorf, Germany · Active not recruiting

  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz

    Mainz, Germany · Recruiting

  • Aichi Cancer Center Hospital

    Aichi, Nagoya, Japan · Recruiting

  • National Cancer Center Hospital East

    Chiba, Kashiwa, Japan · Recruiting

  • Sendai Kousei Hospital

    Miyagi, Sendai, Japan · Completed

  • Osaka International Cancer Institute

    Osaka, Osaka, Japan · Recruiting

  • Kindai University Hospital

    Osaka, Sakai, Japan · Recruiting

Showing 40 of 59 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.